Others | Pharmaceuticals
November 02, 2018
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals is the pharma arm of the Torrent Group. The company
Stock Info
specializes in cardiovascular, diabetes and central nervous system (CNS).
Chronic and sub-chronic therapies form 75% of the portfolio (52% of Indian
Market Cap (` cr)
pharma market). Nearly 39% of the revenue is generated domestically while the
52 Week High / Low
rest is earned from US, Germany, Brazil and ROW markets. Torrent Pharma
Avg. Daily Volume
made 5 acquisitions since 2014. The latest one, Unichem Laboratories, helped
Face Value (`)
the company in elevating its position among peers to number 5 from number 13.
BSE Sensex
Torrent-Unichem integration will be completed by FY19. The company expects
further synergies from this acquisition. It also expects ~25% growth from the US
Reuters Code
market. Currently, Torrent has 51 US ANDA monetisation in the pipeline, which
Bloomberg Code
was just 16 in FY16. Further, it plans to launch 8-9 products in FY19. The
company has made huge investment in FY18 in capacity expansion and
acquisitions. An investment in caopex worth `2 bn is also planned for FY19,
which is expected to increase production. Revenues and profits of the company
Shareholding Pattern (%)
are growing at a healthy rate. It registered an 18.1% and 19.1% CAGR in sales
and PAT over FY2009-18. Torrent Pharma has also delivered 3-year average
ROE of 29.4%. Hence Buy.
MF / Banks / Indian Fls
Indian Public / Others
Abs. (%)
3m 1yr
Jaikishan Parmar
022 - 3935 7600 Ext: 6810
[email protected]
Please refer to important disclosures at the end of this report
Torrent Pharmaceuticals |Pharmaceuticals
Research Team Tel: 022 - 39357600
E-mail: [email protected]
Website: www.angelbroking.com
Angel Broking Limited (hereinafter referred to as “Angel”) is a registered Member of National Stock Exchange of India Limited, Bombay
Stock Exchange Limited and Metropolitan Stock Exchange Limited. It is also registered as a Depository Participant with CDSL and
Portfolio Manager with SEBI. It also has registration with AMFI as a Mutual Fund Distributor. Angel Broking Limited is a registered entity
with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH000000164. Angel
or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities
Market. Angel or its associates/analyst has not received any compensation / managed or co-managed public offering of securities of
the company covered by Analyst during the past twelve months.
This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment
decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make
such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies
referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and
risks of such an investment.
Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and
trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's
fundamentals. Investors are advised to refer the Fundamental and Technical Research Reports available on our website to evaluate the
contrary view, if any.
The information in this document has been printed on the basis of publicly available information, internal data and other reliable
sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this
document is for general guidance only. Angel Broking Limited or any of its affiliates/ group companies shall not be in any way
responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report.
Angel Broking Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify,
nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While
Angel Broking Limited endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory,
compliance, or other reasons that prevent us from doing so.
This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced,
redistributed or passed on, directly or indirectly.
Neither Angel Broking Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in
connection with the use of this information.
Disclosure of Interest Statement
Torrent Pharmaceuticals
1. Financial interest of research analyst or Angel or his Associate or his relative
2. Ownership of 1% or more of the stock by research analyst or Angel or associates or relatives
3. Served as an officer, director or employee of the company covered under Research
4. Broking relationship with company covered under Research
Ratings (Based on expected returns
Buy (> 15%)
Accumulate (5% to 15%)
Neutral (-5 to 5%)
over 12 months investment period):
Reduce (-5% to -15%)
Sell (< -15)